- Home
- TEAF vs FDMT Comparison
TEAF vs FDMT Comparison
Compare TEAF & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEAF
- FDMT
- Stock Information
- Founded
- TEAF 2017
- FDMT 2013
- Country
- TEAF United States
- FDMT United States
- Employees
- TEAF N/A
- FDMT N/A
- Industry
- TEAF Trusts Except Educational Religious and Charitable
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- TEAF Finance
- FDMT Health Care
- Exchange
- TEAF Nasdaq
- FDMT Nasdaq
- Market Cap
- TEAF 163.0M
- FDMT 192.2M
- IPO Year
- TEAF N/A
- FDMT 2020
- Fundamental
- Price
- TEAF $12.21
- FDMT $4.26
- Analyst Decision
- TEAF
- FDMT Buy
- Analyst Count
- TEAF 0
- FDMT 10
- Target Price
- TEAF N/A
- FDMT $32.33
- AVG Volume (30 Days)
- TEAF 56.1K
- FDMT 397.4K
- Earning Date
- TEAF 01-01-0001
- FDMT 08-07-2025
- Dividend Yield
- TEAF 9.20%
- FDMT N/A
- EPS Growth
- TEAF N/A
- FDMT N/A
- EPS
- TEAF N/A
- FDMT N/A
- Revenue
- TEAF N/A
- FDMT $23,000.00
- Revenue This Year
- TEAF N/A
- FDMT $11,586.49
- Revenue Next Year
- TEAF N/A
- FDMT N/A
- P/E Ratio
- TEAF N/A
- FDMT N/A
- Revenue Growth
- TEAF N/A
- FDMT N/A
- 52 Week Low
- TEAF $11.11
- FDMT $2.24
- 52 Week High
- TEAF $13.30
- FDMT $19.69
- Technical
- Relative Strength Index (RSI)
- TEAF 58.26
- FDMT 55.84
- Support Level
- TEAF $12.13
- FDMT $4.19
- Resistance Level
- TEAF $12.23
- FDMT $4.42
- Average True Range (ATR)
- TEAF 0.10
- FDMT 0.24
- MACD
- TEAF -0.02
- FDMT 0.00
- Stochastic Oscillator
- TEAF 46.44
- FDMT 84.62
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a USA-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.